AU2018249816B2 - Mineral coated microparticles for sustained delivery of biologically active molecules - Google Patents

Mineral coated microparticles for sustained delivery of biologically active molecules Download PDF

Info

Publication number
AU2018249816B2
AU2018249816B2 AU2018249816A AU2018249816A AU2018249816B2 AU 2018249816 B2 AU2018249816 B2 AU 2018249816B2 AU 2018249816 A AU2018249816 A AU 2018249816A AU 2018249816 A AU2018249816 A AU 2018249816A AU 2018249816 B2 AU2018249816 B2 AU 2018249816B2
Authority
AU
Australia
Prior art keywords
antagonist
active agent
mineral
formulation
mps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018249816A
Other languages
English (en)
Other versions
AU2018249816A1 (en
Inventor
Connie CHAMBERLAIN
Anna CLEMENTS
William Murphy
Ray Vanderby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of AU2018249816A1 publication Critical patent/AU2018249816A1/en
Application granted granted Critical
Publication of AU2018249816B2 publication Critical patent/AU2018249816B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2018249816A 2017-04-03 2018-04-03 Mineral coated microparticles for sustained delivery of biologically active molecules Active AU2018249816B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762480710P 2017-04-03 2017-04-03
US62/480,710 2017-04-03
PCT/US2018/025913 WO2018187344A1 (en) 2017-04-03 2018-04-03 Mineral coated microparticles for sustained delivery of biologically active molecules

Publications (2)

Publication Number Publication Date
AU2018249816A1 AU2018249816A1 (en) 2019-10-17
AU2018249816B2 true AU2018249816B2 (en) 2025-04-17

Family

ID=63712804

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018249816A Active AU2018249816B2 (en) 2017-04-03 2018-04-03 Mineral coated microparticles for sustained delivery of biologically active molecules

Country Status (10)

Country Link
US (1) US12465654B2 (cg-RX-API-DMAC7.html)
EP (1) EP3606512A4 (cg-RX-API-DMAC7.html)
JP (1) JP7170031B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190130643A (cg-RX-API-DMAC7.html)
CN (1) CN110691588A (cg-RX-API-DMAC7.html)
AU (1) AU2018249816B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019020373A2 (cg-RX-API-DMAC7.html)
CA (1) CA3058802A1 (cg-RX-API-DMAC7.html)
IL (1) IL269607A (cg-RX-API-DMAC7.html)
WO (1) WO2018187344A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3058802A1 (en) 2017-04-03 2018-10-11 Wisconsin Alumni Research Foundation Mineral coated microparticles for sustained delivery of biologically active molecules
WO2022051247A1 (en) * 2020-09-01 2022-03-10 Dianomi Therapeutics, Inc. Methods for treating or preventing inflammatory events
DE102020129648A1 (de) * 2020-11-10 2022-05-12 Leopold MTX GmbH Pharmazeutische zusammensetzung
CN114917364A (zh) * 2022-05-12 2022-08-19 云南大学附属医院 一种携IL-8和Anakinra双配体靶向纳米微泡的制备方法
WO2024102801A2 (en) * 2022-11-09 2024-05-16 Wisconsin Alumni Research Foundation Mineral-coated iron oxide microparticles and use of same including use for immunomodulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008041704A1 (fr) * 2006-10-02 2008-04-10 National Institute For Materials Science Préparation à libération contrôlée
US20160017368A1 (en) * 2013-02-19 2016-01-21 Wisconsin Alumni Research Foundation Inorganic coatings for the enhancement of chemical transfection

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
TWI267378B (en) * 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
JP2003212756A (ja) * 2002-01-21 2003-07-30 Olympus Optical Co Ltd 薬剤徐放剤
MXPA06014126A (es) * 2004-06-04 2007-07-18 Regeneron Pharma Metodos para utilizar antagonistas il-1 para tratar enfermedades auto-inflamatorias.
US7655758B2 (en) * 2004-08-17 2010-02-02 Regeneron Pharmaceuticals, Inc. Stable liquid IL-1 antagonist formulations
US7473678B2 (en) * 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
IN2014DN09128A (cg-RX-API-DMAC7.html) * 2005-09-14 2015-07-10 Mannkind Corp
US20100143439A1 (en) * 2007-04-16 2010-06-10 University Of Toledo Hybrid Biomimetic Particles, Methods of Making Same and Uses Therefor
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
US20090111763A1 (en) * 2007-10-26 2009-04-30 Celonova Biosciences, Inc. Loadable polymeric particles for bone augmentation and methods of preparing and using the same
US9011965B2 (en) 2008-02-29 2015-04-21 Smith & Nephew, Inc. Gradient coating for biomedical applications
US20100015049A1 (en) * 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
CA2740633C (en) * 2008-09-25 2019-02-26 Tissue Regeneration Systems, Inc. Mineral-coated microspheres
JP6827960B2 (ja) 2015-03-03 2021-02-10 ティーアールエス ホールディングス リミテッド ライアビリティ カンパニー コーティングスキャフォールド
EP3283125B1 (en) 2015-04-17 2021-12-29 CureVac Real Estate GmbH Lyophilization of rna
CA3058802A1 (en) 2017-04-03 2018-10-11 Wisconsin Alumni Research Foundation Mineral coated microparticles for sustained delivery of biologically active molecules
WO2019010304A1 (en) 2017-07-05 2019-01-10 Wisconsin Alumni Research Foundation MICROPARTICLES COATED WITH MINERALS FOR GENES ADMINISTRATION IN CHRONIC WOUND THERAPY
CA3068917A1 (en) 2017-07-05 2019-01-10 Wisconsin Alumni Research Foundation Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes
EP3556728A1 (en) 2018-04-16 2019-10-23 Croda Denmark A/S Organically modified mineral micro-particles, methods of preparing the same and uses thereof
US20190358344A1 (en) 2018-05-23 2019-11-28 Dianomi Therapeutics, Inc. Mineral coated microparticles for sustained delivery of steroids
US20240325596A1 (en) 2021-11-09 2024-10-03 Wisconsin Alumni Research Foundation Mineral-coated substrates for stabilization of rna-based therapeutic compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008041704A1 (fr) * 2006-10-02 2008-04-10 National Institute For Materials Science Préparation à libération contrôlée
US20160017368A1 (en) * 2013-02-19 2016-01-21 Wisconsin Alumni Research Foundation Inorganic coatings for the enhancement of chemical transfection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MANSKY, RG: "Blocking Interleukin-1 in Rheumatic Diseases: Its Initial Disappointments and Recent Successes in the Treatment of Autoinflammatory Diseases", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 1182, no. 1, 2009, pages 111 - 123 *
YU , X ET AL.: "Multilayered Inorganic Microparticles for Tunable Dual Growth Factor Delivery", ADVANCED FUNCTIONAL MATERIALS, vol. 24, no. 20, 28 May 2014 (2014-05-28), pages 1 - 22, XP055543732 *

Also Published As

Publication number Publication date
BR112019020373A2 (pt) 2020-04-28
US20200164087A1 (en) 2020-05-28
WO2018187344A1 (en) 2018-10-11
JP7170031B2 (ja) 2022-11-11
US12465654B2 (en) 2025-11-11
EP3606512A4 (en) 2021-01-13
IL269607A (en) 2019-11-28
AU2018249816A1 (en) 2019-10-17
KR20190130643A (ko) 2019-11-22
CA3058802A1 (en) 2018-10-11
JP2020513033A (ja) 2020-04-30
CN110691588A (zh) 2020-01-14
EP3606512A1 (en) 2020-02-12

Similar Documents

Publication Publication Date Title
AU2018249816B2 (en) Mineral coated microparticles for sustained delivery of biologically active molecules
Nich et al. Macrophages—key cells in the response to wear debris from joint replacements
CN101677537B (zh) 解联蛋白变体及其药学用途
JP2020189878A (ja) 抗炎症剤としてのｐｒｇ４の使用
CN102389413B (zh) 用于治疗糖尿病的组合物及其应用
AU2014346051B2 (en) Use of IL-22 dimers in manufacture of medicaments for treating pancreatitis
EP4596046A2 (en) Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
AU2015292582A1 (en) Collagen IV replacement
JP2022081677A (ja) 線維症の処置のためのインターフェロン－ラムダの医学的使用
JP2024520202A (ja) Ｉｌ－２３に対する抗体及びｔｎｆアルファに対する抗体の組み合わせ療法を用いた炎症性腸疾患を治療する方法
WO2019213686A1 (en) Therapeutic compositions and uses therefor
EP2925341B1 (en) Peptide compounds and methods of production and use thereof
HK40014557A (en) Mineral coated microparticles for sustained delivery of biologically active molecules
WO2022051247A1 (en) Methods for treating or preventing inflammatory events
JP2024502825A (ja) 抗体の局所的延長放出
Hao et al. Drug-free mesenchymal stem cell-mimicking nanodecoys suppress inflammation and attenuate new bone formation in ankylosing spondylitis
Wang et al. Exploring the multi-repair effects of advanced biomimetic rapamycin nanoparticles on cerebral ischemia-reperfusion injury
WO2022146925A1 (en) Extended local release of antibodies
Egashira et al. Novel biological strategies for treatment of wear
Torres et al. Listeria Infection.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)